Pharmanovia

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about
Pharmanovia, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Pharmanovia please access Flcube.comFineline Info & Tech (Flcube.com) provides you with comprehensive information about Pharmanovia, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Pharmanovia please access Flcube.com

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion
Company

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion

Eli Lilly and Company (NYSE: LLY) reported third‑quarter 2026 worldwide revenue of USD 24.4 billion, up 39% year‑on‑year, driven by strong demand for its diabetes and obesity treatments Mounjaro (tirzepatide)…

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
IMPACT Therapeutics and Pharmanovia Receive Positive CHMP Opinion for Sepalna (Senaparib) – PARP1/2 Inhibitor Set for EU First‑Line Ovarian Cancer Maintenance
CompanyDrug

IMPACT Therapeutics and Pharmanovia Receive Positive CHMP Opinion for Sepalna (Senaparib) – PARP1/2 Inhibitor Set for EU First‑Line Ovarian Cancer Maintenance

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million
CompanyDeals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

CompanyDeals

Pharmanovia Bolsters Neurology Portfolio with Acquisition of Sanofi’s CNS Products